000040969 000__ 03229nam\a2200313Ia\4500
000040969 001__ 40969
000040969 003__ SzGeWIPO
000040969 005__ 20231124113422.0
000040969 006__ m\\\\\o\\d\\\\\\\\
000040969 007__ cr\un|||||||||
000040969 008__ 160519s2016\\\\mau\\\\eob\\\\001\0\eng\\
000040969 020__ $$a9781785369377$$qeBook
000040969 020__ $$a9781785369384$$qPrint
000040969 040__ $$aSzGeWIPO$$beng$$erda$$dSzGeWIPO
000040969 041__ $$aeng
000040969 042__ $$apcc
000040969 050_4 $$aK1401$$b.Y84 2016
000040969 1001_ $$aYu, Helen.
000040969 24510 $$aAchieving Proof of Concept in Drug Discovery and Development :$$bThe Role of Competition Law in Collaborations between Public Research Organizations and Industry.
000040969 260__ $$aNorthampton, MA :$$bEdward Elgar Pub.,$$c2016.
000040969 300__ $$a288 pages.$$ccm.
000040969 504__ $$aIncludes bibliographical references and index.
000040969 5050_ $$aPart I. landscape of drug discovery and development -- 1. Introduction -- 2. The pharmaceutical industry and drug development models -- 3. Intellectual property rights and competition law in collaborative drug development between industry and integrated drug discovery organizations -- Part II. analysis and application of EU competiton law to the integrated drug discovery model -- 4. Application of competition law to the integrated drug discovery model: research and development block exemption regulation -- 5. Application of competition law to the integrated drug discovery model: technology transfer block exemption regulation -- Part III. case study: agreements between industry and integrated drug discovery organizations -- 6. Analysis of collaboration agreements between integrated drug discovery organizations and industry -- Part IV. conclusion -- 7. Conclusion and implications.
000040969 520__ $$aOne of the major shortcomings of the current drug discovery and development process is the inability to bridge the gap between early stage discoveries and pre-clinical research in order to advance innovations beyond the discovery phase. This book examines a drug discovery and development model, where the respective expertise of academia and industry are brought together to take promising discoveries through to proof of concept, providing a means to de-risk the drug discovery and development process. Expert author Helen Yu explores integrated drug discovery by analyzing the intersection of intellectual property law and competition law and discusses the role of stakeholders in the efficient translation and commercialization of publically funded research. Considering the transactional risks associated with drug discovery and development, this book advocates for a greater emphasis on contractual freedom and economic efficiency when assessing collaborative partnerships between industry and public research organizations. This standout book bridges the gap between theoretical research and legal practice by providing a research-based applied perspective on university-industry collaborations in drug discovery and development. Achieving Proof of Concept in Drug Discovery and Development has an international appeal, especially in countries actively involved in drug discovery and development. Organizations and associations will also benefit from a research-based applied perspective that advocates for a more nuanced application of the law to the pharmaceutical industry.
000040969 588__ $$aDescription based on print record.
000040969 650_0 $$aIntellectual property.
000040969 650_0 $$aDrug development.
000040969 655_0 $$aElectronic books.
000040969 85641 $$uhttps://www.elgaronline.com/view/9781785369384.xml$$yView eBook
000040969 904__ $$aBook
000040969 980__ $$aOS